2017 Interventions of Interest:

TNF Inhibitors

  • Adalimumab (Humira®, Abbvie)
  • Certolizumab pegol (Cimzia®, UCB)
  • Etanercept (Enbrel®, Amgen)
  • Golimumab (Simponi®, Janssen)
  • Infliximab (Remicade®, Janssen)

CD20- Directed Cytolytic Antibody

  • Rituximab (Rituxan®, Genentech)

T Cell Inhibitor

  • Abatacept (Orencia®, BMS)

IL-6 Inhibitors

  • Sarilumab (Kevzara®, Sanofi and Regeneron Pharmaceuticals)
  • Tocilizumab (Actemra®, Genentech)

JAK- Inhibitors

  • Tofacitinib (Xeljanz®, Pfizer)
  • Baricitinib (Olumiant®, Eli Lilly and Co.)

Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, affecting approximately 1.5 million Americans. RA is more common in women and may occur at any age, with peak incidence occurring at ages 50-60 years. RA is typically characterized by morning stiffness and symmetrical joint swelling of the feet, hands, and knees, although any joint (and in some cases, internal organs) may be involved. The course of RA may be complicated by cardiac, hematologic, and other extra-articular manifestations.

The final Report and Meeting Summary reviewed evidence on 11 targeted immunomodulator drugs, including sarilumab and baricitinib. They highlighted actions for payers, manufacturers, clinical societies, and other stakeholders to improve patient care while controlling costs.

For questions, please contact info@icer.org.

View the Key Stakeholders List.


Final Documents

Below you will find the final documents from the assessment review process:

Public Comments on Draft Evidence ReportDownload
Report-At-A-GlanceDownload
Final Evidence Report and Meeting SummaryDownload

ICER’s President Steve Pearson, MD, MSc stated:

“Since the late 1990s, TIMs have contributed to a revolutionary shift in how RA is treated. Evidence suggests these drugs are highly effective, and patients attest to their life-changing effects. Their high costs, however, lead payers to institute step therapy and prior authorization requirements that are often based on the level of rebate provided and are difficult for both patients and physicians to navigate. Too many patients struggle to access the therapies they need and miss out on the advances in treatment that they provide. Our hope is that our report and public meeting will bring new perspectives to manufacturers, payers, and other stakeholders who can work towards a system in which we can reward innovation while ensuring that patients are able to access the treatment most clinically appropriate for their needs.”